Xu Bowen, Chen Zhiqiang, Zhang Jing, Chang Jianhua, Zhao Wei, Dong Zhaoru, Zhi Xuting, Li Tao
Department of Hepatobiliary Surgery, General Surgery, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
Department of Surgery, Yidu Central Hospital of Weifang City, Weifang, China.
Front Oncol. 2021 Jun 28;11:707742. doi: 10.3389/fonc.2021.707742. eCollection 2021.
Gallbladder carcinoma (GBC) is a rare gastrointestinal malignancy with poor prognosis. Adequate pre-treatment prediction of survival is essential for risk stratification and patient selection for aggressive surgery or adjuvant therapeutic strategy. Whole blood cell count (WBCC) derived indexes are broadly used as prognosticative biomarkers in various cancer types, but their utility in GBC needs to be validated.
An extensive literature review was conducted in line with PRISMA guideline until June 31 2020, to identify original studies concerning WBCC-derived indexes as prognostic indicators in GBC. All relative parameters were extracted and pooled for statistical analyses.
Fourteen studies incorporating 2,324 patients were included with a high quality and low risk of biases. All 14 studies evaluated the prognostic value of NLR showing a significant correlation with OS in GBC patients (HR = 1.94, 0.001). Elevated NLR was revealed to correlate with TNM stage (stages III and IV, OR = 4.65, 0.001), tumor differentiation (OR = 2.37, 0.042), CA 19-9 (SMD = 0.47, = 0.01), but no significance was found with age, sex and CEA. Positive indicative value of MLR and PLR were also confirmed with a HR of 2.06 (0.001) and 1.34 (0.001), respectively.
The WBCC-derived indexes including NLR, MLR/LMR and PLR were validated to be useful prognostic parameters for predicting survival outcomes in GBC patients. These series of indexes, especially NLR, could improve risk stratification and facilitate better patient selection for surgical resection or aggressive chemotherapy in the decision making of GBC patients.
胆囊癌(GBC)是一种罕见的胃肠道恶性肿瘤,预后较差。充分的生存预治疗预测对于风险分层以及积极手术或辅助治疗策略的患者选择至关重要。全血细胞计数(WBCC)衍生指标在多种癌症类型中被广泛用作预后生物标志物,但其在GBC中的效用需要验证。
按照PRISMA指南进行广泛的文献综述,直至2020年6月31日,以确定有关WBCC衍生指标作为GBC预后指标的原始研究。提取所有相关参数并汇总进行统计分析。
纳入了14项研究,共2324例患者,质量高且偏倚风险低。所有14项研究均评估了中性粒细胞与淋巴细胞比值(NLR)的预后价值,显示其与GBC患者的总生存期(OS)显著相关(风险比[HR]=1.94,P<0.001)。结果显示,NLR升高与肿瘤-淋巴结-转移(TNM)分期(III期和IV期,比值比[OR]=4.65,P<0.001)、肿瘤分化(OR=2.37,P=0.042)、糖类抗原19-9(标准化均数差[SMD]=0.47,P=0.01)相关,但与年龄、性别和癌胚抗原(CEA)无关。单核细胞与淋巴细胞比值(MLR)和血小板与淋巴细胞比值(PLR)的阳性指示价值也得到证实,HR分别为2.06(P<0.001)和1.34(P<0.001)。
包括NLR、MLR/LMR和PLR在内的WBCC衍生指标被证实是预测GBC患者生存结果的有用预后参数。这一系列指标,尤其是NLR,可改善风险分层,并在GBC患者的决策中有助于更好地选择手术切除或积极化疗的患者。